找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Radiopharmaceutical Therapy; Lisa Bodei,Jason S. Lewis,Brian M. Zeglis Book 2023 The Editor(s) (if applicable) and The Author(s), under ex

[复制链接]
楼主: 召集会议
发表于 2025-3-27 01:01:36 | 显示全部楼层
发表于 2025-3-27 01:33:44 | 显示全部楼层
发表于 2025-3-27 07:21:41 | 显示全部楼层
Dosimetry in Radiopharmaceutical Therapyhealthy tissue. The utility and efficacy of a targeted radiotherapeutic procedure arise from the interplay between the physiological distribution of a radiopharmaceutical, the emitted particles of the associated radionuclide, the subject’s anatomy, and radiobiologic factors. The characterization of
发表于 2025-3-27 11:29:37 | 显示全部楼层
发表于 2025-3-27 16:02:03 | 显示全部楼层
Case Study #1: Alpha Particle Therapy of Leukemia Using 225Ac-Lintuzumabessed on acute myeloid leukemia (AML) cells. The name “actinium” is derived from the Greek . meaning “ray” or “beam,” and the decay of each actinium-225 atom produces 4 alpha (α) particles during the cascade to stable .Bi. Lintuzumab (HuM195) is a humanized immunoglobulin G (IgG) that was selected f
发表于 2025-3-27 18:30:11 | 显示全部楼层
Case Study #2: Disialoganglioside GD2 as a Target for Radiopharmaceutical Therapycluding neuroblastoma, osteosarcoma, soft tissue sarcomas, and others. Dinutuximab (chimeric 14.18) and naxitamab (humanized 3F8 or hu3F8) are Food and Drug Administration (FDA)-approved monoclonal antibodies (mAb) that are specific for the penta-oligosaccharide epitope in GD2. Immuno-oncology, radi
发表于 2025-3-27 22:42:33 | 显示全部楼层
发表于 2025-3-28 05:08:01 | 显示全部楼层
发表于 2025-3-28 08:54:33 | 显示全部楼层
Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapyolabelled peptide designed to target receptors overexpressed on tumor cells. The most frequently employed target for PRRT in clinical practice is the somatostatin receptor (SSTR), which is overexpressed on a range of tumor cells including neuroendocrine tumors (NETs). In this case study, we describe
发表于 2025-3-28 13:22:09 | 显示全部楼层
Case Study #5: CXCR4-Targeted Radiotherapeuticsoendocrine neoplasms or common cancers such as prostate carcinoma. In recent years, RPT has been expanded towards the treatment of hematological neoplasms, in particular by targeting C-X-C motif chemokine receptor 4 (CXCR4). To this end, the most comprehensively evaluated theranostic pair is compose
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-9 21:50
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表